NASH
Fibrosis

Dyslipidaemia
Atherosclerosis

PRECLINICAL CRO SERVICES FOR DRUGS TARGETING METABOLIC DISORDERS

Physiogenex provides preclinical in vivo and ex vivo CRO services with more than 15 years of expertise in evaluating drugs targeting metabolic disorders such as obesity, diabetes, NASH, fibrosis, diabetic nephropathy, cardiovascular complications, dyslipidemia and atherosclerosis.

We develop in-house and gold standard preclinical models in our cutting-edge facilities near Toulouse, France.

Along with our preclinical CRO services, we offer consulting services adapted to the specific needs of our clients. Our metabolic diseases experts offer their many years of experience in drug development to help you design and run efficient and cost-effective studies to shorten your product’s time to market.

STATE OF THE ART CRO FACILITIES

Physiogenex is located near Toulouse (France) in brand new facilities . Our technical platform is equipped with all appropriate devices to ensure high quality CRO services and reliable study results to our clients.

Learn more

High success rate customer satisfaction in 2021: 97.5%

When is your turn?

US Biotech customer

“Excellent scientific advice provided for the study design. Studies tailored for small biotechs with limited budget. Timelines met, rigor in execution. Indeed, a great partner for drug development in the metabolic disease area.”

European Biotech customer

« Great working with Physiogenex: great competence in the area, straight answer and very good team available to support all our needs »

US Pharma customer

“I can’t thank you enough for all your great work and support! It was really nice collaborating with you all and I am very much looking forward to the next collaboration with you!”

Indian Pharma customer

“High level of expertise and timely discussions during the study plan and execution Very co-operative”

South American Pharma customer

“Once again, I would like to appreciate for all your assistance during the study execution and all technical issues that Physiogenex experts helped us to understand. Physiogenex is a very strategic partner and in the future, we certainly will consider you to perform our preclinical studies.”

Korean Pharma customer

“We really appreciate what you did for our study. A new assay development was successful. The study report was well-documented.”

THEY TRUST US

We work with more than 100 biopharmaceutical, nutraceutical and agrifood companies

LATEST NEWS ABOUT PHYSIOGENEX

Physiogenex to exhibit at booth#51 and present a new DIO NASH mouse study at the ILC-EASL 2022 in London, UK on June the 25th, 2022

by François Briand | Jun 21, 2022 | 2022

Physiogenex will be exhibiting at booth#51 and presenting a new DIO-NASH mouse study (abstract#258) at the ILC-EASL in London, UK, on June 25th, 2022. The...

Physiogenex to present the effects of clinical benchmarks in its obese NASH hamster model at the Keystone Symposia “Tissue Fibrosis and Repair”, June 12-16, Keystone, CO, USA

by François Briand | Jun 10, 2022 | 2022

Physiogenex will be presenting the effects of clinical benchmarks in its innovative obese NASH hamster model on June the 13th, 2022 at the Keystone Symposia...

Physiogenex to present a new DIO NASH mouse study at the American Diabetes Association 2022 in New Orleans, LA, USA on June the 6th, 2022

by François Briand | Jun 2, 2022 | 2022

Physiogenex will be presenting a new DIO-NASH mouse study at the 82nd Scientific Sessions of the American Diabetes Association in New Orleans, LA, USA, June...